Kambiz Yazdi Analyst PerformanceAnalyst at BTIG ResearchKambiz Yazdi is a stock analyst at BTIG Research in the healthcare sector, covering 10 publicly traded companies. Over the past year, Kambiz Yazdi has issued 44 stock ratings, including strong buy, buy, and hold recommendations. While full access to Kambiz Yazdi's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kambiz Yazdi's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings46 Last 1 YearsBuy Recommendations97.78% 44 Buy RatingsCompanies Covered10 Unique Companies Ratings Distribution45RatingsDistribution of strong buy, buy, hold, and sell ratings by Kambiz Yazdi.RatingPercentageCount Strong Buy8.9%4 ratings Buy88.9%40 ratings Hold2.2%1 ratings Sell0.0%0 ratingsOut of 45 total stock ratings issued by Kambiz Yazdi at BTIG Research, the majority (88.9%) have been Buy recommendations, followed by 8.9% Strong Buy and 2.2% Hold.Best & Worst CallsBest Call000.0%AVTXMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ARQTMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ10 companiesKambiz Yazdi, an analyst at BTIG Research, currently covers 10 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare10 companies100.0%Kambiz Yazdi of BTIG Research specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentagePHARMACEUTICALS5 companies50.0%BIOTECHNOLOGY5 companies50.0% Kambiz Yazdi's Ratings History at BTIG Research Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsRAPPRapport Therapeutics8/19/2026Reiterated Rating$49.01$65.00Buy$0.0000.00% ROIEYPTEyepoint Pharmaceuticals8/17/2026Lower Price Target$4.62$8.00Buy$0.0000.00% ROIABSIAbsci8/12/2026Reiterated Rating$9.41$13.00Buy$0.0000.00% ROISIONSionna Therapeutics8/10/2026Downgrade$4.67Neutral$0.0000.00% ROIRAPPRapport Therapeutics8/5/2026Reiterated Rating$42.01$65.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines7/29/2026Reiterated Rating$295.81$810.00Buy$0.0000.00% ROIZVRAZevra Therapeutics7/27/2026Lower Price Target$9.52$24.00Buy$0.0000.00% ROIRAPPRapport Therapeutics7/16/2026Reiterated Rating$39.93$65.00Buy$0.0000.00% ROIVTVTvTv Therapeutics7/16/2026Boost Price Target$32.69$57.00Buy$0.0000.00% ROIKZIANovogen7/15/2026Reiterated Rating$13.57$34.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. KZIANovogen7/1/2026Initiated Coverage$14.08$34.00Buy$0.0000.00% ROIABSIAbsci6/24/2026Boost Price Target$10.30$13.00Buy$0.0000.00% ROIZVRAZevra Therapeutics6/9/2026Reiterated Rating$13.17$27.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines6/2/2026Reiterated Rating$335.16$810.00Buy$0.0000.00% ROIABSIAbsci5/28/2026Initiated Coverage$5.16$9.00Buy$0.0000.00% ROIABSIAbsci5/28/2026Initiated Coverage$6.75$9.00Buy$0.0000.00% ROIRAPPRapport Therapeutics5/21/2026Boost Price Target$35.72$65.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines5/20/2026Reiterated Rating$320.61$843.00Buy$0.0000.00% ROISIONSionna Therapeutics5/13/2026Reiterated Rating$40.94$58.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines5/8/2026Reiterated Rating$333.28$843.00Buy$0.0000.00% ROIRAPPRapport Therapeutics5/8/2026Reiterated Rating$39.93$53.00Buy$0.0000.00% ROISIONSionna Therapeutics4/27/2026Reiterated Rating$38.12$58.00Buy$0.0000.00% ROIRAPPRapport Therapeutics4/22/2026Reiterated Rating$36.78$53.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines4/6/2026Reiterated Rating$314.50$843.00Buy$0.0000.00% ROIZVRAZevra Therapeutics3/16/2026Initiated Coverage$9.98$23.00Buy$0.0000.00% ROIVTVTvTv Therapeutics3/11/2026Reiterated Rating$34.33$49.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines3/9/2026Reiterated Rating$312.31Buy$0.0000.00% ROIRAPPRapport Therapeutics3/9/2026Boost Price Target$30.85$47.00Buy$0.0000.00% ROISIONSionna Therapeutics3/2/2026Reiterated Rating$33.73$58.00Buy$0.0000.00% ROIVTVTvTv Therapeutics1/27/2026Reiterated Rating$33.86$49.00Buy$0.0000.00% ROISIONSionna Therapeutics1/14/2026Reiterated Rating$36.81$58.00Buy$0.0000.00% ROISIONSionna Therapeutics1/7/2026Boost Price Target$37.22$58.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines12/29/2025Reiterated Rating$268.95$843.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines12/8/2025Set Price Target$247.99$507.00$0.0000.00% ROIRAPPRapport Therapeutics12/8/2025Reiterated Rating$29.50$47.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines12/5/2025Reiterated Rating$189.97$499.00Buy$0.0000.00% ROIVTVTvTv Therapeutics11/19/2025Initiated Coverage$30.11$40.00Buy$0.0000.00% ROISIONSionna Therapeutics11/19/2025Initiated Coverage$39.12$50.00Buy$0.0000.00% ROIRAPPRapport Therapeutics11/19/2025Initiated Coverage$25.32$47.00Buy$0.0000.00% ROIPRAXPraxis Precision Medicines11/18/2025Set Price Target$184.13$424.00Buy$0.0000.00% ROIThe retirement stock I'd buy before Nvidia today (Ad)In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Chaikin Money Flow indicator has a new top retirement pick. The company holds three fast-growing businesses -- including an autonomous vehicle unit and a streaming service with 10x Netflix's reach -- any of which could be spun off in the next 12 to 24 months. It also pays a dividend, a rarity among high-growth AI names. Chaikin lays out the full case in a new free presentation, no email or credit card required.Get Marc Chaikin's free presentation on this overlooked AI stock nowPRAXPraxis Precision Medicines11/18/2025Upgrade$189.32Strong-Buy$0.0000.00% ROIRAPPRapport Therapeutics11/18/2025Upgrade$26.88Strong-Buy$0.0000.00% ROISIONSionna Therapeutics11/18/2025Upgrade$38.41Strong-Buy$0.0000.00% ROIVTVTvTv Therapeutics11/18/2025Upgrade$32.24Strong-Buy$0.0000.00% ROIAVTXAvalo Therapeutics3/25/2025Initiated Coverage$7.63$23.00Buy$00.0000.00% ROIARQTArcutis Biotherapeutics3/11/2025Boost Price Target$15.13$19.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
